TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: BMI at age 7 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI increase from age 3 to 7 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Well-Controlled asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Totally Controlled asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain scores during mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom days reported
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of gastric and duodenal ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency and degree of endoscopic worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Systolic Blood Pressure (SBP) differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic Blood Pressure (DBP) differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in mean HbA(1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in left ventricular perfusion defect size (PDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean fecal incontinence episodes per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain levels (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival somatosensory sensitivity to warmth and painful heat stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in mechanical sensitivity of the gingiva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of pruritus requiring nalbuphine
Endpoint domain: Adverse events/effects
Primary endpoint: Time to full motor function recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum high-density lipoprotein (HDL) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sweat chloride concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of CVD symptoms
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Knowledge of CVD risk factors
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Aneurysms growth ≥5 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMVJ height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preferred decision making style achievement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Effectiveness of manipulation and mobilization for chronic low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of manipulation and mobilization for chronic post-traumatic headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of A4FTp
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contact with healthcare system up to 30 days before OHCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contact with healthcare system up to 1 year before OHCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of complete success at 48 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications frequency after procedures
Endpoint domain: Adverse events/effects
Primary endpoint: report of skill difficulty during school years
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Abrupt closure
Endpoint domain: Adverse events/effects
Primary endpoint: Responder rate (≥50% reduction in seizure frequency)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Seizure-free rate for at least 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in MPI compared with placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline in hyperopia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability in spherical equivalent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-month recurrence of AF
Endpoint domain: Mortality/survival
Primary endpoint: 1-year recurrence of AF
Endpoint domain: Mortality/survival
Primary endpoint: incidence of mild or greater depression symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physical function (SF-36 PCS scores)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: foreign body sensation
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of midazolam, zidovudine/lamivudine, and oral contraceptive steroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily step count at 6 months post-TKR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weekly physical activity at 6 months post-TKR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating levels of miR‐3135b
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: GRACE risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of time pH was <4.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of acidic reflux episodes >5 minutes in duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Chlamydia trachomatis (Ct) detection prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Volume of nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consent-related communication and understanding
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tolerance of instillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hypertension outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LARC uptake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: adequate sedation at 30 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adequate sedation at 45 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective mood-altering effects of morphine
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patellar kinematics and PF contact pressure distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior knee pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PF functional performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: reaction time on a composite attention measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: calm ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Detection thresholds of basic tastes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of apoptosis in the gastric mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Resistance during ETT passage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken for ETT passage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: procedure-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: 4-year disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: PDI scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: MDI scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of brain injury on MRI
Endpoint domain: Adverse events/effects
Primary endpoint: Average percentage PCO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average PCO severity grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual axis clarity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in distress and depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in behavioural disturbance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: adherence rate to PFME
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 6 month improvement in left-ventricular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: levels of adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: interference scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall satisfaction/ease of use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cognition improvement (ADAS-cog)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in Unified Parkinson's Disease Rating Scale motor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum retinol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: LDL-C improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diabetic knowledge scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of cytomegalovirus disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Morbidity of cytomegalovirus disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma urate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma allantoin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MPO activity in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients with high BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of days with home BP readings per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistence with the intervention until delivery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maternal Socioeconomic Status (SES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in VAS for ongoing pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elevation of skin temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pain threshold level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary Incontinence (UI) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Impact on Quality of Life (QoL) as measured by ICIQ-Short Form
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Erectile function as measured by IIEF-5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Emergency department visits
Endpoint domain: Mortality/survival
Primary endpoint: Dose-limiting toxicity of hyperbilirubinemia
Endpoint domain: Adverse events/effects
Primary endpoint: Death within 30 days after last dose
Endpoint domain: Mortality/survival
Primary endpoint: Onset of moderate/severe pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial Infarction (MI) events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urgency urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life item
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequency of honorary authorship
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: technical checklist score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: critical omissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of urine LAM testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Average time for laryngoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cormack and Lehane grade 2 view on laryngoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AQP8 expression level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ocular complications rate (OCR)
Endpoint domain: Adverse events/effects
Primary endpoint: heart failure score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ankle edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intimal Media Thickness (IMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: BBS (Berg Balance Scale) mean difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sperm quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delay in acrophase of agitation rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregivers' ratings of agitation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of life-threatening neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of life-threatening infections
Endpoint domain: Adverse events/effects
Primary endpoint: recovery of initial cognitive status
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in HSRT mean scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in micturitions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in urgency episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median proportion of chest compressions done to the correct depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Criteria for panic disorder fulfillment
Endpoint domain: Mortality/survival
Primary endpoint: Dimensional changes of dentures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total occlusion of grafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intravessel thrombus presence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ventilatory Efficiency (VE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily servings of fruits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent energy from fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diet quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: POIS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in HDRS-17 total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negativity for HCV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal toxicity (proteinuria)
Endpoint domain: Adverse events/effects
Primary endpoint: MIVC (Maximal Isometric Voluntary Contraction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CR (Corneal Radius)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of EOF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sputum smear conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: %SMHC of enamel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wear of enamel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tPA-Act
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PAI-1-Ag
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in treatment decision-making
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal LP-induced anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Histologic criteria for IgG4-related lymphadenopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of gastrointestinal adverse drug reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of hepatic adverse drug reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: blood asymmetric dimethylarginine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Estrone sulfate (E1S) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sex hormone binding globulin (SHBG) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prevalence of goitre among children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean IQ of study population
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Heart Rate Recovery (HRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence rates of Grade 3-4 leucopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence rates of Grade 3-4 neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: ACCM guideline met
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: airway obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: daily symptom scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Activation markers accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Haemocompatibility of the prototype polyacrylonitrile (PAN) membrane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in elastase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global cognitive trajectory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: verbal memory trajectory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Half-emptying time (t(50))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: level of intestinal FDG uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of children with no emetic episodes and no use of rescue medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to onset of emesis or rescue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time from study drug administration until discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Predictive Value (PPV) for cancer detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Negative Predictive Value (NPV) for cancer detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: emergency department resource utilization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: immediate patient outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma angiotensin converting enzyme activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the cough reflex to inhaled capsaicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: facility-based delivery rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: proportion of women receiving quality ANC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: frequency of ANC visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Beat-to-beat BRS reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean terminal plasma elimination half-life of 6β-naltrexol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes